- Report
- July 2024
- 288 Pages
Global
From €5389EUR$5,885USD£4,350GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- November 2021
- 620 Pages
Global
From €3791EUR$4,000USD£3,167GBP
Enfuvirtide is a drug used to treat HIV infection. It is a fusion inhibitor, meaning it works by blocking the virus from entering the cells of the body. It is used in combination with other antiretroviral drugs to help reduce the amount of virus in the body and prevent further damage to the immune system. Enfuvirtide is typically used in patients who have not responded to other treatments or who have developed resistance to other drugs. It is administered as an injection and is usually taken twice daily.
Enfuvirtide is a relatively new drug and is still in the early stages of development. It is not widely available and is only approved for use in certain countries. Despite this, it has been shown to be effective in treating HIV infection and is becoming increasingly popular.
The Enfuvirtide market is an emerging market within the Infectious Diseases Drugs sector. It is expected to grow in the coming years as more countries approve its use and more patients become aware of its benefits.
Some companies in the Enfuvirtide market include Gilead Sciences, Merck, and ViiV Healthcare. Show Less Read more